Billionaire Profile
Clemens Fischer
Global Rank
#3359

Image: Mverho | CC BY-SA 4.0 | via Wikimedia Commons

Clemens Fischer

CEO, Pharmaceuticals
GERMANY
Real-Time Net Worth
$1.027B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
0% (24h)
Age
50
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Clemens Fischer is a German serial entrepreneur and investor with an estimated net worth of $1.0 billion. Born in 1975, Fischer holds a doctorate in Medicine, a master's in Economics, and an MBA from Harvard Business School. His wealth stems from the pharmaceuticals industry, where he founded Futrue Group, a Munich-based holding company that controls over 20 healthcare companies. Before establishing Futrue, Fischer held positions at Novartis, including a role on the German executive board. His career highlights include founding and selling several companies in the over-the-counter drug and supplement space. Fischer's current focus is Vertanical, a company developing a cannabis-based extract for chronic pain treatment.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life

Clemens Fischer was born in Weilheim, Germany, on May 28, 1975. He earned a doctorate in medicine, a master's in Economics, and an MBA from Harvard Business School..

Rise to Success

Fischer's career began in the pharmaceutical industry. Before founding Futrue, he worked at Novartis, where he was a member of the German executive board. His entrepreneurial journey includes founding Futrue Group, a Munich-based holding company that manages over 20 healthcare companies. Fischer has built and sold various companies within the over-the-counter drug and supplement sector, including Naturwohl Pharma, which he sold to Perrigo.

Key Business Strategies

Fischer's strategy involves identifying market opportunities, developing products, and successfully positioning them. This is evident in his sale of companies like Naturwohl Pharma and the listing of PharmaSGP on the stock exchange. Fischer is currently focused on Vertanical, a pharmaceutical company developing a cannabinoid-based extract to treat chronic pain. His approach involves seeking approval for the drug Ver-01 in the European Union and the United States, aiming to create the first cannabis-based prescription painkiller.

Philanthropy

There is no readily available information regarding Clemens Fischer's specific philanthropy amounts. However, his focus on developing treatments suggests a commitment to improving healthcare outcomes.

Career Milestones

2001

Left Medicine

Stopped practicing medicine to pursue an MBA at Harvard and become an entrepreneur

2001-2008

Novartis

Worked for Novartis, holding positions including a role on the German executive board

2009

PharmaSGP GmbH

Founded PharmaSGP GmbH, serving as Chairman-Supervisory Board

2008

Futrue GmbH

Founded Futrue GmbH, serving as Chief Executive Officer

2011

Kijimea Reizdarm

Brought the first probiotic medical product for the treatment of irritable bowel syndrome to market

2016

Sold Naturwohl Pharma

Sold Naturwohl Pharma to Perrigo

2017

Founded Vertanical

Founded Vertanical to develop a cannabinoid-based extract for chronic pain

Philanthropy & Social Impact

Healthcare

Research in Healthcare

$Unknown

Supports research and development of new medical treatments and technologies

Business Philosophy & Leadership

Notable Quotes

"I usually end up with the boring things no one wants to do"

Leadership Principles

Innovation

Focuses on developing innovative pharmaceutical products

Strategic Focus

Concentrates on identifying market opportunities and building successful companies

Vision

Driven by a vision for a world without chronic pain, particularly through the development of new treatments